CN116249716A - Mic抗体和结合剂及其使用方法 - Google Patents

Mic抗体和结合剂及其使用方法 Download PDF

Info

Publication number
CN116249716A
CN116249716A CN202180047612.4A CN202180047612A CN116249716A CN 116249716 A CN116249716 A CN 116249716A CN 202180047612 A CN202180047612 A CN 202180047612A CN 116249716 A CN116249716 A CN 116249716A
Authority
CN
China
Prior art keywords
binding agent
amino acid
ser
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180047612.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·D·吴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kangyu Co ltd
Original Assignee
Kangyu Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kangyu Co ltd filed Critical Kangyu Co ltd
Publication of CN116249716A publication Critical patent/CN116249716A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180047612.4A 2020-07-07 2021-07-06 Mic抗体和结合剂及其使用方法 Pending CN116249716A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063049012P 2020-07-07 2020-07-07
US63/049,012 2020-07-07
PCT/US2021/040445 WO2022010847A1 (en) 2020-07-07 2021-07-06 Mic antibodies and binding agents and methods of using the same

Publications (1)

Publication Number Publication Date
CN116249716A true CN116249716A (zh) 2023-06-09

Family

ID=77127088

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180047612.4A Pending CN116249716A (zh) 2020-07-07 2021-07-06 Mic抗体和结合剂及其使用方法

Country Status (9)

Country Link
US (2) US12139539B2 (enExample)
EP (1) EP4178678A1 (enExample)
JP (1) JP2023532852A (enExample)
KR (2) KR20230152783A (enExample)
CN (1) CN116249716A (enExample)
AU (1) AU2021305084A1 (enExample)
CA (1) CA3184940A1 (enExample)
TW (1) TW202216776A (enExample)
WO (1) WO2022010847A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023076883A1 (en) * 2021-10-27 2023-05-04 Samyang Biopharm Usa Inc. Anti-mic antibodies with variant fc domains
WO2023225626A2 (en) * 2022-05-20 2023-11-23 Adanate, Inc. Multi-targeting lilrb antibodies and uses thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
AU4226999A (en) 1998-06-02 1999-12-20 Dendreon Corporation Method for preparation and (in vivo) administration of antigen presenting cell composition
US20030167531A1 (en) 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
US6512162B2 (en) 1998-07-10 2003-01-28 Calgene Llc Expression of eukaryotic peptides in plant plastids
CA2356215C (en) 1998-12-23 2015-11-24 Pfizer Inc. Human monoclonal antibodies to ctla-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
BR0014945A (pt) 1999-10-21 2004-08-31 Monsanto Co Modificação pós-traducional de proteìnas recombinantes produzidas em plantas
WO2001039594A2 (en) 1999-12-03 2001-06-07 Dendreon Corporation Cryopreservation of antigen-loaded dendritic cells and their precursors in serum-free media
WO2001054732A1 (en) 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
CA2403964C (en) 2000-03-30 2013-04-30 Dendreon Corporation Compositions and methods for dendritic cell-based immunotherapy
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
ES2744275T3 (es) 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
EP2330201B1 (en) 2003-10-22 2017-04-05 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
EP2314618A3 (en) 2004-11-12 2011-10-19 Xencor Inc. Fc variants with altered binding to FcRn
US20080196111A1 (en) 2005-03-18 2008-08-14 Innate Pharma S.A. Expression Vectors and Methods for Obtaining Nk Cell Specific Expression
WO2008036981A1 (en) 2006-09-22 2008-03-27 Dana-Farber Cancer Research, Inc. Methods for treating mica-related disorders
ES2550384T3 (es) 2008-12-18 2015-11-06 Dana-Farber Cancer Institute, Inc. NKG2D-Fc para la inmunoterapia
WO2012091756A1 (en) 2010-12-30 2012-07-05 Avidbiotics Corp. Non-natural mic proteins
KR20160044598A (ko) 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
US8753640B2 (en) 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
PE20142361A1 (es) 2011-09-30 2015-01-16 Dana Farber Cancer Inst Inc Peptidos terapeuticos
SG11201404177PA (en) 2012-02-07 2014-08-28 Innate Pharma Mica binding agents
WO2014130657A1 (en) 2013-02-20 2014-08-28 The Trustees Of The University Of Pennsylvania Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
EP3666886A1 (en) 2013-03-15 2020-06-17 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
JP6450381B2 (ja) * 2013-07-05 2019-01-09 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション がんを処置するための可溶性ｍｉｃ中和モノクローナル抗体
EP4026909A1 (en) 2013-12-19 2022-07-13 Novartis AG Human mesothelin chimeric antigen receptors and uses thereof
CN106459917B (zh) 2014-04-23 2021-03-09 朱诺治疗学股份有限公司 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
EP3145953A1 (en) 2014-05-21 2017-03-29 Dana-Farber Cancer Institute, Inc. Methods for treating cancer with anti bip or anti mica antibodies
WO2016028896A1 (en) 2014-08-19 2016-02-25 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
SG11201703203RA (en) 2014-10-20 2017-05-30 Juno Therapeutics Inc Methods and compositions for dosing in adoptive cell therapy
TWI718118B (zh) 2015-01-16 2021-02-11 美商奇諾治療有限公司 針對ｒｏｒ１之特異性抗體及嵌合抗原受體
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
US20180355318A1 (en) 2015-04-29 2018-12-13 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
JP2018517415A (ja) 2015-06-10 2018-07-05 ナントクエスト インコーポレイテッド がんを処置するための改変ｎｋ−９２細胞
TN2018000187A1 (en) 2015-12-04 2019-10-04 Dana Farber Cancer Inst Inc Vaccination with mica/b alpha 3 domain for the treatment of cancer
AU2016366677A1 (en) 2015-12-09 2018-07-26 Nantcell, Inc. Compositions and methods for treatment of HER2 positive metastatic breast cancer
AU2017344411A1 (en) 2016-10-19 2019-05-09 Novelogics Biotechnology, Inc. Antibodies to MICA and MICB proteins
JP2019535250A (ja) 2016-10-29 2019-12-12 ジェネンテック， インコーポレイテッド 抗ｍｉｃ抗体及び使用方法
CN110418839B (zh) 2017-03-08 2023-06-09 免疫生物公司 用于临床的修饰的NK-92haNK003细胞
IL269553B2 (en) 2017-03-27 2025-10-01 Nat Univ Singapore Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
WO2019004550A1 (ko) 2017-06-26 2019-01-03 강원대학교 산학협력단 Mic-1 단백질에 특이적으로 결합하는 항체 및 이의 용도
US12036241B2 (en) 2017-07-19 2024-07-16 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
AU2018311096A1 (en) 2017-08-04 2020-01-30 Nantkwest, Inc. Treating and inhibiting leukemia with NK-92 cells
ES2992909T3 (en) 2017-08-09 2024-12-19 Juno Therapeutics Inc Methods and compositions for preparing genetically engineered cells
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
KR102761890B1 (ko) 2018-03-23 2025-02-06 브리스톨-마이어스 스큅 컴퍼니 Mica 및/또는 micb에 대한 항체 및 그의 용도
CN113056484B (zh) 2018-07-31 2025-01-14 库利南Mica公司 阻断mica/b脱落的抗mica/b抗体及其使用方法
CN113474450A (zh) 2018-08-09 2021-10-01 朱诺治疗学股份有限公司 产生工程化细胞的方法以及所述工程化细胞的组合物
AU2019366960A1 (en) * 2018-10-23 2021-05-27 Vor Biopharma, Inc. Fc silenced antibody drug conjugates (ADCs) and uses thereof
US20220288225A1 (en) 2019-08-23 2022-09-15 Northwestern University Materials and methods for activating antigen-specific t cell responses
WO2023076883A1 (en) 2021-10-27 2023-05-04 Samyang Biopharm Usa Inc. Anti-mic antibodies with variant fc domains

Also Published As

Publication number Publication date
US12139539B2 (en) 2024-11-12
WO2022010847A1 (en) 2022-01-13
US20230235065A1 (en) 2023-07-27
JP2023532852A (ja) 2023-08-01
KR102594083B1 (ko) 2023-10-25
TW202216776A (zh) 2022-05-01
US20250026837A1 (en) 2025-01-23
AU2021305084A1 (en) 2023-02-02
KR20230012072A (ko) 2023-01-25
KR20230152783A (ko) 2023-11-03
EP4178678A1 (en) 2023-05-17
CA3184940A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
JP6831426B2 (ja) 腫瘍治療のための抗体組成物
TWI695012B (zh) Ｃｄｈ１９及ｃｄ３抗體構築體
JP2025060941A (ja) Ｃｄ１２３結合性ポリペプチド及びその使用
JP7571347B2 (ja) ＣＬＥＣ１２ａ結合性ポリペプチド及びその使用
JP2022515611A (ja) 二重特異性抗ｍｕｃ１６×抗ｃｄ２８抗体およびその使用
US20180072811A1 (en) Anti-cspg4 reagents and methods of treating cancer
JP7525510B2 (ja) Ｃｄ３３結合性ポリペプチド及びその使用
US20250026837A1 (en) MIC Antibodies and Binding Agents and Methods of Using the Same
JPWO2020004492A1 (ja) Ｃｅｌｌ Ａｄｈｅｓｉｏｎ Ｍｏｌｅｃｕｌｅ３に結合する抗体
CN105431205B (zh) 抑制肿瘤转移的IgE抗体
JP7257967B2 (ja) 抗ｐｄ１抗体試薬に関する方法および組成物
US11623953B2 (en) Antibody constructs and methods of treating cancer
EP4624492A1 (en) Anti-ccr8 antibody and use thereof
US20250230246A1 (en) Anti-mic antibodies with variant fc domains
HK40087490A (zh) Mic抗体和结合剂及其使用方法
JP2024529907A (ja) Ｔ細胞機能の疲弊を処置し、がん免疫療法を強化するためのｍｃｔ１１抗体
KR20230154981A (ko) 항-인간 cxcr5 항체 및 이의 용도
WO2023143478A1 (en) Novel anti-cd4 and anti-pd-l1 bispecific antibodies
EA046221B1 (ru) Cd33-связывающие полипептиды и их применение
EA046257B1 (ru) Clec12a-связывающие полипептиды и их применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40087490

Country of ref document: HK